These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29218254)

  • 21. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
    Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
    Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
    Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
    Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary chemotherapy and delayed surgery for osteosarcoma of the extremities with synchronous metastases.
    Ferrari S; Avella M; Briccoli A; Ruggieri P; Casadei R; Lari S; Picci P; Gherlinzoni F; Monti C; Bacci G
    Ann Oncol; 1992 Apr; 3 Suppl 2():S39-41. PubMed ID: 1622863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
    Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
    Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.
    Bacci G; Forni C; Ferrari S; Longhi A; Bertoni F; Mercuri M; Donati D; Capanna R; Bernini G; Briccoli A; Setola E; Versari M
    J Pediatr Hematol Oncol; 2003 Nov; 25(11):845-53. PubMed ID: 14608193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The correlation of Tc-99m MIBI scintigraphy and histological response in determining the percentage of tumor necrosis in osteosarcoma after preoperative chemotherapy.
    Punyaratabandhu T; Wittayawongsaruji S; Rajchadara S; Thanakit V; Charoenvareekul S; Khunkitti N; Songpatanasilp T
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S53-62. PubMed ID: 16862675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteosarcoma chemotherapy effect: a prognostic factor.
    Raymond AK; Chawla SP; Carrasco CH; Ayala AG; Fanning CV; Grice B; Armen T; Plager C; Papadopoulos NE; Edeiken J
    Semin Diagn Pathol; 1987 Aug; 4(3):212-36. PubMed ID: 3313606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma.
    Gorlick R; Liao AC; Antonescu C; Huvos AG; Healey JH; Sowers R; Daras M; Calleja E; Wexler LH; Panicek D; Meyers PA; Yeh SD; Larson SM
    Clin Cancer Res; 2001 Oct; 7(10):3065-70. PubMed ID: 11595696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
    Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
    J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signature of the vascular tumor microenvironment as a marker of the therapeutic response to doxorubicin in a preclinical model of osteosarcoma.
    Crenn V; Amiaud J; Gomez-Brouchet A; Potiron V; Gouin F; Rosset P; Nail LL; Vidal L; Bertin H; Brion R; Tran G; Verrecchia F; Corre I; Redini F
    Am J Cancer Res; 2022; 12(4):1843-1854. PubMed ID: 35530297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.
    Trujillo-Paolillo A; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia Filho RJ; de Oliveira R; de Toledo SRC
    Oncotarget; 2017 Jun; 8(24):38530-38540. PubMed ID: 28404946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
    Bruheim S; Xi Y; Ju J; Fodstad O
    Clin Cancer Res; 2009 Dec; 15(23):7161-9. PubMed ID: 19920113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.
    Robl B; Botter SM; Pellegrini G; Neklyudova O; Fuchs B
    J Exp Clin Cancer Res; 2016 Jul; 35(1):113. PubMed ID: 27421768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors.
    Picci P; Bacci G; Ferrari S; Mercuri M
    Ann Oncol; 1997 Nov; 8(11):1107-15. PubMed ID: 9426330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
    Lindner NJ; Scarborough MT; Spanier SS; Enneking WF
    J Cancer Res Clin Oncol; 1998; 124(10):575-80. PubMed ID: 9829862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preoperative adjuvant therapy for primary malignant bone tumors].
    Goto T; Okuma T; Nakada I; Hozumi T; Kondo T
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1750-4. PubMed ID: 18030009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
    Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
    Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.